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Abstract Four different somatic mutations (F63lC, T6321, D633E, and D633Y) in the putative 6th transmembrane helix of the human thyrotropin 
receptor (TSHR) were recently described in hyperfunctioning thyroid adenomas [Porcellini et al. (1994) J. Clin. Endocrinol. Metab. 79, 657-6611. 
We transiently expressed these mutant receptors in Cos-7 cells and measured [“‘I]TSH binding, basal and TSH-stimulated CAMP production, and 
phosphatidylinositol hydrolysis. The concentration of receptors expressed at the cell surface was lower for the mutants than for the wild type (WT) 
TSHR. Compared to the WT, all four mutant receptors caused a marked increase in basal CAMP levels, but did not increase basal production of 
inositol phosphates. This suggests that autonomous thyroid function and adenoma formation may be related to constitutive activation of the CAMP 
pathway alone. A cluster of conserved residues at the base of the 6th transmembrane helix of the TSHR and other glycoprotein hormone receptors 
appears important for maintaining an inactive receptor conformation. 
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1. Introduction 
Members of the G protein-coupled receptor family share a 
similar predicted topology, consisting of seven transmembrane- 
spanning a-helical domains. The ability of certain amino acid 
substitutions in the C-terminal portion of the third intracellular 
loop to cause agonist-independent activation was first demon- 
strated in vitro for the adrenergic receptors [l-3], and subse- 
quently for the thyrotropin receptor (TSHR) [4]. Naturally 
occurring, constitutively activating mutations of glycoprotein 
hormone receptor genes can serve as the basis of human dis- 
ease: somatic and germline mutations of the TSHR are found 
in hyperfunctioning thyroid adenomas [5]) and autosomal dom- 
inant thyroid hyperplasia [6], respectively, and inherited muta- 
tions of the lutropin receptor (LHR) are the cause of familial 
male precocious puberty (FMPP) [7,8]. In these cases, autono- 
mous endocrine activity has been attributed to hormone-inde- 
pendent activation of the CAMP signaling pathway [5-71. 
Porcellini and coworkers [9] recently reported 4 new missense 
mutations of the TSHR (F631C, T6321, D633E, and D633Y) 
in hyperfunctioning thyroid adenomas. The three affected resi- 
dues are located in the 6th transmembrane helix, and two of 
them (T632 and D633) correspond to LHR residues which were 
previously found to be mutated in FMPP [7,8,10] (Fig. 1). 
Glycoprotein hormone receptors not only mediate CAMP pro- 
duction, but are also capable of stimulating the phosphatidyli- 
nositol (PI) hydrolysis cascade that leads to production of dia- 
cylglycerol and inositol phosphates (IP) [I 1,121. In order to 
better understand the role of the 6th transmembrane domain 
in the activation mechanism of glycoprotein hormone recep- 
tors, we transiently expressed the 4 new mutant TSHR in Cos-7 
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cells and measured [‘251]TSH binding, basal and TSH-stimu- 
lated CAMP production, and PI hydrolysis. 
2. Materials and methods 
2.1. Mutagenesis 
Human TSHR cDNA [13] was inserted into the EcoRI site of 
M 13mpl8 vector and oligonucleotide-mediated, site-directed mut- 
agenesis was used to generate clones encoding the desired mutation as 
previously described [4,14,15]. Residue numbers are determined by 
counting from the methionine start site. WT and mutant clones were 
inserted into the EcoRI site of the pSG5 expression vector. Mutations 
were confirmed by DNA sequencing of the Iinal construct and plasmid 
DNA was purified by CsCl gradient ultracentrifugation. 
2.2. Transfection 
Transfection of Cos-7 cells with mutant or WT human TSHR or 
pSG5 vector DNA was performed by electroporation [4,14-171; 25 pg 
purified plasmid DNA was used in each. Aliquots of the same batch 
of transfected cells were plated for TSH binding and assays of CAMP 
and IP production; medium was inositol free in the latter assays and 
supplemented with 2.5 @i/ml myo-[2-‘H(N)]inositol (DuPont-NEN, 
Boston, MA). 
2.3. Assays 
All the assays were initiated simultaneously 48 h after transfection 
and after washing with assay buffer: Hanks’ Balanced Salt Solution 
containing 0.5% crystalline BSA, and 20 mM HEPES at pH 7.4. 
[‘2SI]TSH binding was measured after incubation for 2 h at 22°C in 1 
ml of NaCl-free assay buffer containing 222 mM sucrose, - 100,000 cpm 
[“‘I]TSH (-4OpCi/pg) and 0 to lo-’ M unlabeled TSH. TotalcAMPand 
IP levels were measured in the same wells after incubation for 1 h at 
37°C with 0.2 ml assay buffer containing 10 mM LiCl, 0.5 mM 3- 
isobutyl-1-methylxanthine, and, as noted, lo-” to lo-’ M TSH. Total 
CAMP was measured by radioimmunoassay and IP formation was 
determined using anion exchange columns [4,16]. 
All assays were performed at least in triplicate, on at least 3 separate 
occasions with different batches of cells, and always included control 
cells transfected with WT DNA or pSG5 vector alone. The program 
LIGAND [18] was used to calculate K,, and B,,,,, values for TSH bind- 
ing. 
Kd data were log-transformed, averaged, and reconverted to calculate 
geometric mean. 95% confidence limit of Kd was obtained by log- 
transformation, calculating mean - 1.96 S.D. and mean + 1.96 S.D., 
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and reconversion (Table 1). CAMP and PI data are expressed as fold 
increase over basal in cells transfected with WT TSHR DNA in Table 
1, and as fold-increase over basal in cells transfected with the pSG5 
vector alone in Fig. 2. 
3. Results 
Binding experiments (Table 1) showed that the four mutant 
receptors were expressed on the cell surface at significantly 
lower concentrations than the WT TSHR (B,,, values 36-59% 
of WT B,,,,,). The affinity of the mutant receptors for TSH was 
slightly increased, but the difference reached statistical signifi- 
cance only for D633E. 
In the absence of TSH, cells transfected with the WT TSHR 
had 2.5-fold higher basal CAMP accumulation than cells trans- 
fected with pSG5 vector alone (Fig. 2A). The agonist TSH 
produced a concentration-dependent increase in CAMP pro- 
duction in cells expressing the WT receptor, with an E& of 
3 x lo-” M and maximal stimulation of 6-fold over basal 
(Fig. 2A, Table 1). 
Cells transfected with each of the four mutant constructs had 
a 3- to 4-fold increase in basal CAMP accumulation compared 
to cells transfected with the WT TSHR, indicating that they 
were constitutively activated (Fig. 2A, Table 1). Mutant recep- 
tors were also capable of responding to increasing concentra- 
tions of TSH with additional CAMP production. Maximal 
TSH-stimulated CAMP production in mutant-transfected cells 
was similar or somewhat lower than that in WT-transfected 
cells, and the EC, values were comparable (Fig. 2A, Table 1). 
Cells expressing WT TSHR did not show increased accumu- 
lation of IP in the absence of agonist (Fig. 2B). TSH produced 
a concentration-dependent increase in IP production, but at 
least lo-” M TSH was required to elicit a response. The max- 
imum concentration of TSH tested (lo-’ M) produced an 8-fold 
stimulation of basal. Unlike the findings with CAMP produc- 
tion, none of the mutant TSHR elicited a significant increase 
in IP production in the absence of TSH (Fig. 2B, Table 1). IP 
production in mutant-transfected cells exposed to lo-’ M TSH 
was lower than that in WT-transfected cells (Fig. 2B, Table 1). 
Table 1 
Characterization of mutant TSH receptors 
Helix 6 Activating Mutations 
TSHR 
@?? 
D633 + Y. E 
T632 -_* ) 
F63’ -c. L 
- 
A623 - I, v 
D619 +G 
0570 + G 
J-577 + 1 
- 
M571 + ( 
- 
D564 + G 
“0 
Fig. 1. Schematic view of the putative 6th transmembrane helix and 
C-terminal portion of the 3rd intracellular loop of the human TSHR. 
Naturally-occurring activating mutations in this region of the TSHR 
and LHR [5,7-10,3@32] are shown. Residues equivalent to TSHR 633, 
626, 623, and 619 may be located on the surface of the a-helix that is 
oriented toward the receptor cleft [26,27]. 
4. Discussion 
The glycoprotein hormone receptors are characterized by 
several common features, including their large extracellular, 
N-terminal hormone binding domains, a conserved pattern of 
residues in their transmembrane domains, and their ability to 
couple dual, G protein-mediated signaling pathways [l 1,121. 
The TSHR and LHR are coupled less efficiently to the PI 
hydrolysis cascade, which is presumably mediated by a member 
of the G, family, than to the G,-mediated CAMP pathway 
[11,12,19,20]. The recent observation that identical disease- 
causing missense mutations occur in the TSHR and LHR (Fig. 
1) suggests that these receptors may share a common molecular 
activation mechanism. 
WT F631C T6321 D633Y D633E 
TSH binding 
& (PM)* 
% B,,, (m**) 
Number of experiments 
455 103 157 
(289-714) (28-379) (6&374) lf;13-155) 
100 44.7 f 7.4 36.1 f 4.1 58.6 f 3.2 58.6 f 0.6 
4 4 3 3 4 
CAMP increase 
%Basal (iWT basal) 100 302 f 4 369 + 18 405 + 8 389 z!z 13 
Max Resp (/WT basal)*** 631 f 22 628 f 52 518 + 37 556 f 17 632 ?r 31 
IP increase 
%Basal (/WT basal) 100 100 + 4 128 + 10 127 + 11 125 f 11 
Max Resp (/WT basal)*** 757 f 191 646 f 141 523 ?r 133 582 f 124 425 f 22 
Number of experiments 5 5 4 5 5 
*Geometric mean. Values in parentheses are 95% confidence limits. 
**WT B,,,, averaged 92.8 f 14.7 fmol/well. 
***Maximal response at lo-‘M TSH. 
The mutant B,,,,,, CAMP, and PI data (mean + S.E.) are expressed as a percentage of WT TSHR values. 
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Fig. 2. Basal and TSH-stimulated accumulation ofCAMP (A) and inositol phosphates (IPn) (B) in Cos-7 cells transfected 48 h earlier with control 
vector (pSG5), wild type human TSHR DNA (WT), or TSHR DNA encoding F631C, T6321, D633E and D633Y mutations. Data are means of 4-5 
experiments, and are expressed asfold-increase over basal in cells transfected with the pSG5 vector alone. 
Characterization of the first four naturally-occurring TSHR 
gene mutations indicated that the encoded substitutions were 
capable of causing agonist-independent production of CAMP, 
but not IP, compared to the WT receptor [5,6]. Two (F631C 
and T6321) of the four new TSHR mutations were shown to 
cause constitutive activation of CAMP-dependent ranscription 
when transfected into mouse fibroblasts, but the ability of these 
mutant receptors to bind TSH and activate PI hydrolysis was 
not studied [9]. We now show that the activating effect of the 
four new mutations, like that of the earlier mutations, is re- 
stricted to the CAMP pathway. The fact that the B,,,,, values of 
the mutant receptors are decreased compared to WT B_ indi- 
cate that increased basal CAMP accumulation is not simply due 
to receptor overexpression, and may explain why maximal 
TSH-stimulated IP production is decreased in the mutants. 
Inactive receptors are thought to exist in a constrained con- 
formation that is relieved by the binding of agonist. The result- 
ing conformational change allows cytoplasmic domains of the 
receptor, including portions of the third intracellular loop, to 
interact productively with G proteins. In theory, activating 
amino acid substitutions may mimic agonist occupancy by in- 
creasing the proportion of receptors that are in the active con- 
formation, or by increasing the affinity of the activated receptor 
for G protein [2]. 
Fig. 2 shows that the WT human TSHR has the capacity to 
activate CAMP production (but not IP production) in the ab- 
sence of agonist. This property has been noted previously with 
the human TSHR [5,6,21], as well as with the rat TSHR 
[4,16,17] and the &adrenergic receptor [2]. The amount of 
CAMP stimulation has been shown to be related to the level of 
receptor expression [2,6,16]. Substitutions of certain residues in 
the third cytoplasmic loop of the rat TSHR are capable of 
eliminating spontaneous receptor activity [4]. 
Unlike the WT TSHR, the closely related LHR is ‘silent’, and 
fails to stimulate basal CAMP production, even when studied 
under the same assay conditions [7,21]. Thus, normal human 
TSHR and LHR appear to have an intrinsic difference in their 
tendency to undergo isomerization and activate G, in the ab- 
sence of agonist [2]. Both the physiological significance and the 
structural basis of this difference remain to be defined. 
Why are the activating effects of the TSHR mutations re- 
stricted to the CAMP pathway? The coupling of glycoprotein 
hormone receptors to the PI hydrolysis pathway is known to 
be inherently less efficient than coupling to the G,-mediated 
CAMP pathway, perhaps because of differences in kinetics, or 
in the nature of the signaling components involved [20]. Rela- 
tively high concentrations of agonist and/or receptor are re- 
quired to elicit stimulation of PI hydrolysis. As noted above, 
the WT TSHR does not stimulate basal IP production. Study 
of a series of different mutant rat TSHR constructs howed that 
receptors that caused constitutive CAMP production (275% 
over basal) were only capable of producing a small increase 
(30-50%) in basal IP levels, while mutant receptors with dimin- 
ished basal CAMP production also lost the ability to mediate 
even TSH-stimulated PI hydrolysis [4]. 
We speculate that the concentration of mutant TSH recep- 
tors that spontaneously assume an activated conformation in 
Cos-7 cells may be adequate to drive CAMP production, but 
inadequate to stimulate a significant increase in PI hydrolysis. 
Regardless of the mechanism, the finding that naturally-occur- 
ring TSHR mutations lead to constitutive activation of CAMP 
signaling, but not PI hydrolysis, suggests that autonomous thy- 
roid function and adenoma formation is primarily related to 
activation of the CAMP pathway. 
Activating mutations in adrenergic receptors not only lead 
to agonist-independent signaling, but also cause dramatic in- 
creases in agonist binding affinity and agonist potency, and 
decreased receptor expression levels [l-3]. Activating muta- 
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tions in the glycoprotein hormone receptors are associated with 
decreased B,, values but little or no increase in agonist affin- 
ities (Table 1, unpublished results). This discrepancy may be 
due to the fact that, unlike the adrenergic receptors, the major 
determinants of agonist affinity in glycoprotein hormone recep- 
tors are residues in the N-terminal domain [11,12], and 
hormone binding by these two classes of receptors is therefore 
regulated differently [22]. 
The localization and characterization of mutations that 
mimic agonist occupancy may provide insight into the normal 
mechanism of receptor activation. Residues at the base of helix 
6 and in the adjacent C-terminal portion of the 3rd intracellular 
loop are thought to play an important role in receptor-G pro- 
tein coupling. Naturally-occurring TSHR mutations in this re- 
gion occur at residues (D619, A623, F631, T632, D633) that are 
perfectly conserved among all mammalian glycoprotein 
hormone receptors and homologous receptors from inverte- 
brates [23,24]. The 3D structure of G protein-coupled receptors 
is unknown, but models of the possible orientation of the trans- 
membrane helices have been constructed [25-271. Specific inter- 
actions between these helices may be critical for maintaining the 
inactive receptor conformation [6,7,25]. 
For example, the effects of amino acid substitutions at D633 
in the TSHR, or at the equivalent aspartate in LHR ([7,28] and 
unpublished results), suggest that the side chain of this residue 
may normally form a stabilizing interhelical hydrogen bond. It 
is unclear why substitutions at the adjacent threonine and phen- 
ylalanine residues are also constitutively activating, but it is 
known that threonine has the potential to participate in stabiliz- 
ing intrahelical hydrogen bonds [29]. Additional study of the 
activating substitutions found in this and other regions [6,30- 
321 may shed light on the mechanism by which the TSHR and 
other glycoprotein hormone receptors normally undergo con- 
formational change. 
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